奥马珠单抗治疗抗肿瘤药物过敏反应。

Omalizumab for management of hypersensitivity reactions to anticancer drugs.

机构信息

Department of Immunology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.

Medical School, The University of Western Australia, Perth, Western Australia, Australia.

出版信息

Intern Med J. 2024 Aug;54(8):1396-1400. doi: 10.1111/imj.16464. Epub 2024 Jul 19.

DOI:10.1111/imj.16464

PMID:39031469

Abstract

Hypersensitivity reactions to anticancer drugs include treatment-limiting toxicity. Standard drug desensitisation offers temporary tolerance and hence requires repetition. We used omalizumab, an anti-immunoglobulin E antibody, to overcome immediate and delayed hypersensitivity reactions to various anticancer drugs. Seven of the eight patients in the current study successfully resumed the desired anticancer drug regimen without standard desensitisation. No safety issues from omalizumab were observed.

摘要

抗肿瘤药物过敏反应包括治疗相关毒性。标准药物脱敏可提供暂时的耐受性，因此需要重复。我们使用奥马珠单抗（一种抗免疫球蛋白 E 抗体）来克服各种抗肿瘤药物的即刻和迟发性过敏反应。当前研究中的 8 名患者中有 7 名成功地恢复了所需的抗肿瘤药物方案，而无需标准脱敏。奥马珠单抗未观察到安全性问题。